We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Agilent Technologies to Acquire Assets of iLab Solutions

By LabMedica International staff writers
Posted on 04 Jul 2016
Print article
Agilent Technologies Inc. (Santa Clara, California, USA) will acquire most of the assets of iLab Solutions, LLC (Boston, Massachusetts, USA), including the company’s technology, intellectual property, product portfolio and employee talent. The acquisition is expected to be completed in early August, subject to local laws and regulations and customary closing conditions.

Agilent provides instruments, software, services and consumables for the entire laboratory workflow to customers in more than 100 countries, while iLab offers cloud-based solutions for core laboratory management to universities, research hospitals and independent institutes. iLab’s offerings allow customers to book time in shared facilities to bill and invoice for projects, manage studies, generate reports and business intelligence, and schedule instrument reservations across multiple projects.

“Our acquisition of iLab further expands our offerings portfolio in a space we previously did not have a presence in,” said Mark Doak, president, Agilent CrossLab Group. “iLab’s solutions are robust and scalable, allowing for expansion into large-enterprise accounts, including Pharma. With iLab’s experience and outstanding enterprise-level management solutions, we will be able to immediately deliver broader value for our customers.”

“Joining forces with Agilent is an excellent fit for us,” said Tad Fallows, chief executive officer, iLab Solutions. “It is also a tremendous opportunity for our customers, who will benefit from integration with a broad family of solutions and a range of new applications. Together, we’ll be able to further accelerate our offerings to additional markets through Agilent’s global reach and leadership in multiple market segments.”

Related Links:
Agilent Technologies
iLab Solutions
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.